Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Published:2024-09 Issue:9 Volume:42 Page:1486-1488
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Eide Christopher A.,Brewer Diana,Xie Tao,Schultz Anna Reister,Savage Samantha L.,Muratcioglu Serena,Merz Noah,Press Richard D.,O’Hare Thomas,Jacob Thomas,Vu Tania Q.,Tognon Cristina E.,Macey Tara A.,Kuriyan John,Kalodimos Charalampos G.,Druker Brian J.

Funder

National Cancer Institute

National Institute of General Medical Sciences

Publisher

Elsevier BV

Reference10 articles.

1. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency;Shah;J. Clin. Invest.,2007

2. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants;Eide;Cancer Cell,2019

3. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors;Jabbour;Blood,2012

4. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro;Eadie;Oncotarget,2018

5. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option;Lipton;Blood Rev.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP